Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

PyrGF and GSTLN peptides enhance pravastatin's inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme

Full text
Author(s):
da Silva, Jaff Ribeiro [1, 2] ; de Cerqueira e Silva, Mariana Barros [2] ; Philadelpho, Biane Oliveira [1] ; de Souza, Victoria Cruz [1] ; Machado dos Santos, Johnnie Elton [1] ; Castilho, Marcelo Santos [1] ; Ferreira, Ederlan de Souza [1] ; Cilli, Eduardo Maffud [2]
Total Authors: 8
Affiliation:
[1] Univ Fed Bahia, Sch Pharm, Barao de Jeremoabo St, BR-40170115 Salvador, BA - Brazil
[2] Sao Paulo State Univ, Inst Chem, UNESP, Rua Prof Francisco Degni, BR-14800060 Araraquara, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: FOOD BIOSCIENCE; v. 44, n. B DEC 2021.
Web of Science Citations: 0
Abstract

Two newly designed peptides, Pyr-GF and GSTLN, enhance pravastatin inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCoAR). In silica experiments have demonstrated the interaction of these peptides with the catalytic and NADPH sites of HMGCoAR. In vitro, the Pyr-GF (IC50 = 117.4 mu M) and GSTLN (IC50 = 278.1 mu M) peptides exhibit dose-dependent inhibition on the HMGCoAR activity, and the effects are more significant than those observed for original peptides obtained from cowpea and adzuki beans. Compared to pravastatin alone, the Pyr-GF/pravastatin combination produced a small decrease (8%) in HMGCoAR activity, whereas the GSTLN/pravastatin combination produced a significant decrease of 41% on HMGCoAR activity. The association between Pyr-GF/GSTLN peptides decreased the IC50 to 71.8 mu M. These results suggest their interaction with different sites; Pyr-GF and pravastatin mainly act on the catalytic site and GSTLN on the NADPH site. Hence, the Pyr-GF and GSTLN peptides and their combination exhibit a cholesterol-lowering effect and act as adjuvants upon association with pravastatin. (AU)

FAPESP's process: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery
Grantee:Glaucius Oliva
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 14/50926-0 - INCT 2014: biodiversity and natural products
Grantee:Vanderlan da Silva Bolzani
Support Opportunities: BIOTA-FAPESP Program - Thematic Grants